期刊
CANCER LETTERS
卷 497, 期 -, 页码 202-211出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2020.09.016
关键词
CHK1; Cell cycle; DNA Damage response
类别
资金
- Department of Defense [W81XWH1810054]
- U.S. Department of Defense (DOD) [W81XWH1810054] Funding Source: U.S. Department of Defense (DOD)
The DNA damage response relies on CHK1 kinase for maintaining genomic integrity, involving in processes such as DNA replication and mitotic progression. While CHK1 has potential in cancer therapy, it has yet to be fully realized clinically.
The DNA damage response enables cells to cope with various stresses that threaten genomic integrity. A critical component of this response is the serine/threonine kinase CHK1 which is encoded by the CHEK1 gene. Originally identified as a regulator of the G2/M checkpoint, CHK1 has since been shown to play important roles in DNA replication, mitotic progression, DNA repair, and overall cell cycle regulation. However, the potential of CHK1 as a cancer therapy has not been realized clinically. Herein we expound our current understanding of the principal roles of CHK1 and highlight different avenues for CHK1 targeting in cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据